We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

155 hedge funds and large institutions have $703M invested in Akebia Therapeutics in 2020 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 54 increasing their positions, 42 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

676% more call options, than puts

Call options by funds: $10.9M | Put options by funds: $1.4M

32% more capital invested

Capital invested by funds: $532M → $703M (+$171M)

29% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 42

23% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 22

1% more funds holding

Funds holding: 153 → 155 (+2)

0.62% more ownership

Funds ownership: 70.83% → 71.45% (+0.62%)

Holders
155
Holders Change
+2
Holders Change %
+1.31%
% of All Funds
3.42%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
27
Increased
54
Reduced
42
Closed
22
Calls
$10.9M
Puts
$1.4M
Net Calls
+$9.48M
Net Calls Change
+$6.58M

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$55.4M
2
FCM
Farallon Capital Management
California
+$9.72M
3
Invesco
Invesco
Georgia
+$8.83M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.7M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$6.45M

Top Sellers

Rank Fund Capital Flow
1
BG
Baupost Group
Massachusetts
-$15.9M
2
Morgan Stanley
Morgan Stanley
New York
-$6.29M
3
Citadel Advisors
Citadel Advisors
Florida
-$5.36M
4
WP
Woodline Partners
California
-$5.03M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.99M
Name Holding Trade Value Shares
Change 		Change in
Stake
WP
26
Woodline Partners
California
$4.75M -$5.03M -646,077 -51%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$4.48M -$788K -101,256 -15%
PIMJS
28
PKO Investment Management Joint-Stock
Poland
$4.15M – – –
Jacobs Levy Equity Management
29
Jacobs Levy Equity Management
New Jersey
$3.77M +$1.06M +136,125 +38%
JP Morgan Chase
30
JP Morgan Chase
New York
$3.64M +$1.5M +192,907 +67%
AG
31
Artal Group
Luxembourg
$3.22M – – –
Massachusetts Financial Services
32
Massachusetts Financial Services
Massachusetts
$2.7M +$372K +47,752 +16%
SLG
33
Stanley-Laman Group
Pennsylvania
$2.42M +$50.3K +6,464 +2%
California Public Employees Retirement System
34
California Public Employees Retirement System
California
$2M +$237K +30,480 +13%
Wells Fargo
35
Wells Fargo
California
$1.84M +$315K +40,510 +20%
Deutsche Bank
36
Deutsche Bank
Germany
$1.8M +$1.22M +156,950 +196%
AI
37
Atom Investors
Texas
$1.7M +$1.75M +224,769 New
Squarepoint
38
Squarepoint
New York
$1.68M +$840K +107,989 +95%
Citadel Advisors
39
Citadel Advisors
Florida
$1.66M -$5.36M -688,939 -76%
Man Group
40
Man Group
United Kingdom
$1.66M -$942K -121,069 -36%
AQR Capital Management
41
AQR Capital Management
Connecticut
$1.65M -$625K -80,356 -27%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$1.63M +$240K +30,789 +17%
Bank of America
43
Bank of America
North Carolina
$1.56M +$412K +52,900 +35%
IHAM
44
Integral Health Asset Management
New York
$1.52M +$1.56M +200,000 New
State of Wisconsin Investment Board
45
State of Wisconsin Investment Board
Wisconsin
$1.38M -$732K -94,066 -34%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$1.35M -$15.7K -2,012 -1%
Morgan Stanley
47
Morgan Stanley
New York
$1.35M -$6.29M -808,653 -82%
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
$1.23M -$282K -36,284 -18%
UBS Group
49
UBS Group
Switzerland
$1.19M -$506K -65,089 -29%
Hudson Bay Capital Management
50
Hudson Bay Capital Management
Connecticut
$1.18M +$428K +55,000 +55%
1
2
3 4 5

AKBA Hedge Fund Activity: Q1 2020 in Review

155 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2020, worth a combined $703M — up 32% from $532M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new AKBA positions and 22 closed out — a net gain of 5 holders — while 54 added to existing stakes and 42 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $55.4M. The largest seller was Baupost Group, cutting an estimated $15.9M.

  • 155 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2020, up from 153 in Q4 2019.
  • Funds reported $703M of Akebia Therapeutics stock for Q1 2020, up 32% quarter-over-quarter.
  • 27 funds opened new Akebia Therapeutics positions in Q1 2020 and 22 closed out, a net change of +5 holders.
  • The largest Akebia Therapeutics buyer in Q1 2020 was Consonance Capital Management, an estimated $55.4M added.
  • The largest Akebia Therapeutics seller in Q1 2020 was Baupost Group, an estimated $15.9M sold.

Based on aggregated 13F filings for Q1 2020.